JPMorgan Chase & Co’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-26,969
| Closed | -$92K | – | 5107 |
|
|
2018
Q3 | $92K | Buy |
26,969
+3,176
| +13% | +$10.8K | ﹤0.01% | 4153 |
|
|
2018
Q2 | $89K | Buy |
23,793
+1,940
| +9% | +$7.26K | ﹤0.01% | 4122 |
|
|
2018
Q1 | $89K | Buy |
21,853
+84
| +0.4% | +$342 | ﹤0.01% | 3970 |
|
|
2017
Q4 | $101K | Buy |
21,769
+19,985
| +1,120% | +$92.7K | ﹤0.01% | 3908 |
|
|
2017
Q3 | $13K | Buy |
1,784
+232
| +15% | +$1.69K | ﹤0.01% | 4020 |
|
|
2017
Q2 | $11K | Buy |
1,552
+319
| +26% | +$2.26K | ﹤0.01% | 4036 |
|
|
2017
Q1 | $8K | Sell |
1,233
-198,462
| -99% | -$1.29M | ﹤0.01% | 4243 |
|
|
2016
Q4 | $1.17M | Buy |
199,695
+146,432
| +275% | +$858K | ﹤0.01% | 2916 |
|
|
2016
Q3 | $283K | Buy |
+53,263
| New | +$283K | ﹤0.01% | 3157 |
|
|
2016
Q1 | – | Sell |
-6,329
| Closed | -$32K | – | 4368 |
|
|
2015
Q4 | $32K | Sell |
6,329
-1,236,870
| -99% | -$6.25M | ﹤0.01% | 3434 |
|
|
2015
Q3 | $4.38M | Sell |
1,243,199
-552,252
| -31% | -$1.94M | ﹤0.01% | 2018 |
|
|
2015
Q2 | $17.9M | Sell |
1,795,451
-23,017
| -1% | -$230K | ﹤0.01% | 1323 |
|
|
2015
Q1 | $23.1M | Buy |
1,818,468
+168,016
| +10% | +$2.14M | 0.01% | 1232 |
|
|
2014
Q4 | $23.4M | Buy |
1,650,452
+558,248
| +51% | +$7.9M | 0.01% | 1208 |
|
|
2014
Q3 | $15M | Sell |
1,092,204
-16,002
| -1% | -$220K | ﹤0.01% | 1435 |
|
|
2014
Q2 | $17M | Sell |
1,108,206
-67,668
| -6% | -$1.04M | ﹤0.01% | 1408 |
|
|
2014
Q1 | $20M | Buy |
1,175,874
+26,921
| +2% | +$459K | 0.01% | 1289 |
|
|
2013
Q4 | $14.9M | Sell |
1,148,953
-1,825,948
| -61% | -$23.6M | ﹤0.01% | 1423 |
|
|
2013
Q3 | $30M | Buy |
2,974,901
+48,778
| +2% | +$492K | 0.01% | 1026 |
|
|
2013
Q2 | $21.9M | Buy |
+2,926,123
| New | +$21.9M | 0.01% | 1126 |
|